Document is current

Article History

Received: 13 August 2020

Accepted: 16 August 2020

First Online: 26 August 2020

Ethics approval and consent to participate

: The study protocol has been approved by the Ethics Committees of the Capital Region of Denmark, reference no. VEK H-20026049 on June 12, 2020. I hereby certify that this trial has received ethical approval from the appropriate ethical committee as described above .Consent is obtained from a physician not involved in the study acting on the patients behalf before any trial related procedure are started as this is a trial in an acute setting and eligible patients for this trial will be temporarily incompetent due to acute severe illness and therefore not able to give informed consent. The Investigator will as soon as possible after inclusion of the patient obtain written consent from the patient or proxy consent from both a physician not involved in the study acting on the patient’s behalf and next-of-kin. Patients, who, during the course of this trial, become able to give consent, will be asked to participate and give their consent even though a proxy consent is obtained.

: Not applicable.

: PIJ is co-inventor on a patent for the biomarker thrombomodulin to identify critically ill patients with endotheliopathy and the use of prostacyclin as a therapy to combat this condition. The remaining authors declare that they have no competing interests